
New CNS partnership between Boehringer and Autifony
The deal gives Boehringer an exclusive option to purchase Autifony’s Kv3.1/3.2 positive modulator platform, and includes lead compound AUT00206, a novel, orally active small molecule currently being assessed in two Phase Ib studies, including one […]